Silver Book Fact

Risedronate, a bisphosphonate, has been shown to reduce vertebral fractures by around 41%, hip fractures by 30%, and non-vertebral fractures by 39%.

Harris, Steven T., Nelson Watts, Harry Genant, Clark McKeever, Thomas Hangartner, Michael Keller, Charles Chesnut III, Jacques Brown, Erik F. Eriksen, Mohammad Hoseyni, Douglas Axelrod, and Paul Miller. Effects of Risedronate Treatment on Vertebral and Nonvertebral Fractures in Women with Postmenopausal Osteoporosis: a Randomized Controlled Trial. JAMA. 1999; 282(14): 1344-52. http://jama.ama-assn.org/cgi/content/abstract/282/14/1344

Reference

Title
Effects of Risedronate Treatment on Vertebral and Nonvertebral Fractures in Women with Postmenopausal Osteoporosis: a Randomized Controlled Trial
Publication
JAMA
Publication Date
1999
Authors
Harris, Steven T., Nelson Watts, Harry Genant, Clark McKeever, Thomas Hangartner, Michael Keller, Charles Chesnut III, Jacques Brown, Erik F. Eriksen, Mohammad Hoseyni, Douglas Axelrod, and Paul Miller
Volume & Issue
Volume 282, Issue 14
Pages
1344-52
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Randomized controlled trials give evidence that pharmacologic therapy can reduce risk of fractures by 40 to 50%.  
  • An Alzheimer’s disease treatment breakthrough that slowed its progression and began to show its effects in 2015, would reduce the costs of care for all people with the disease by…  
  • Patients with vertebral fractures who underwent kyphoplasty, a procedure that stabilizes fractures of the spine, were found in one study to have reduced pain, fewer new fractures, and less healthcare…  
  • 30 drugs are currently in development for osteoporosis.  
  • Raloxifene, a selective estrogen receptor modulator (SERM) has been shown to increase vertebral bone mineral density (BMD) by 2% to 3% after 3 years.